## PFE: Pfizer, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.0% below STRENGTH zone (3.0-6.0%); PEG 3.77 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Pfizer price leans on SMA support - Forecast today - 03-12-2025**
- Source: Economies.com | 20251203T123600 | Somewhat-Bullish | Relevance: 99%
- Pfizer (PFE) is showing negative signals from RSI indicators but is expected to rise in upcoming trading, supported by its 50-day SMA and an ascending trend, provided it remains above $24.95, targeting a resistance level at $26.10. Meanwhile, Caterpillar (CAT) is preparing to break resistance at $596.20, although overbought RSI levels may limit rapid gains. Bitcoin and Ethereum are also navigating overbought conditions while attempting to maintain gains and break resistance levels respectively.

**2. Pfizer Partner 3SBio To Raise $400 Million In Stock Sale**
- Source: Forbes | 20251202T234800 | Bullish | Relevance: 99%
- 3SBio, a Chinese partner of Pfizer, plans to raise approximately $400 million through a share placement, primarily for research and development. This follows a previous agreement in July where Pfizer invested $100 million in 3SBio, aiming to advance cancer medicines. The collaboration highlights continued U.S.-China ties in healthcare despite broader trade tensions, with 3SBio's shares soaring over 300% in the past year.

**3. Pfizer Inc. (PFE) stock price, news, quote and history**
- Source: Yahoo Finance Singapore | 20251202T005140 | Neutral | Relevance: 98%
- This article provides a comprehensive overview of Pfizer Inc. (PFE) stock, including its current price, historical data, and key financial metrics. It details the company's product offerings, therapeutic areas, and collaboration agreements, alongside performance over various periods and analyst insights. The page also features earnings trends, valuation measures, and tools to compare Pfizer with similar pharmaceutical companies.

**4. Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure**
- Source: www.sharewise.com | 20251202T162400 | Bullish | Relevance: 98%
- Pfizer is experiencing growth in its oncology division, driven by a strong portfolio of cancer medicines and the strategic acquisition of Seagen. Despite competitive pressures and declining sales for some older drugs like Ibrance, newer therapies and a robust pipeline are contributing to increased revenues. The company expects to have eight or more blockbuster oncology medicines by 2030, reinforcing oncology as a central driver for its long-term outlook, even as its stock performance lags the industry.

**5. November Social Media Round-Upâ€”Third-Quarter Earnings, Metsera Acquisition, and More**
- Source: Pfizer | 20251203T133000 | Bullish | Relevance: 98%
-  This article provides a round-up of Pfizer's social media activities in November, highlighting third-quarter earnings, the acquisition of Metsera, and various initiatives. Key announcements include CEO Albert Bourla's update on the Metsera acquisition and strong Q3 results, as well as new video series launches and the Pfizer Foundation's 2025 Citizens Award win. The article also touches on awareness campaigns for lung cancer and efforts to promote vaccination against respiratory illnesses.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Guggenheim | $35 | $33 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Guggenheim | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 12 ($0.22M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 31.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.4% (+0.2%)
- Blackrock Inc.: 8.8% (+0.5%)
- State Street Corpora: 5.3% (+0.9%)
- Geode Capital Manage: 2.3% (+1.2%)
- Morgan Stanley: 1.3% (+6.6%)

### Key Risks

1. Valuation stretched: PEG 3.8x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.77 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 16%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +6%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $144.0B |
| Beta | 0.42 |
| 52W Range | $20.92 - $27.69 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.77 |
| Forward P/E | 8.3 |
| Current P/E | 8.2 |
| YoY Growth | -1.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 4.0pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.99% (CS: 41) | Neutral |
| RSI_14 | 55.2 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 1.015x | Above |
| vs SMA50 | 1.021x | Above |
| vs SMA200 | 1.041x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $25.57
- **Stop Loss:** $24.37 (4.7% risk)
- **Target:** $26.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 791
- **Position Value:** $20,225.87
- **Portfolio %:** 20.23%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite. VIX at 16 is below median, showing calm, but breadth is only moderate and put/call is neutral, suggesting neither strong bullish nor defensive extremes. Key drivers are rising Fed rate-cut odds from soft ADP jobs data, mixed earnings across sectors, and ongoing AI/tech strength offset by caution in cyclicals and banks. Positioning should remain selective and neutral, awaiting more decisive macro or earnings signals.*

### Earnings

**Next:** 2026-02-03 (Est: $0.60)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.63 | $0.87 | +37.4% |
| 2025Q2 | $0.57 | $0.78 | +35.9% |
| 2025Q1 | $0.67 | $0.92 | +36.5% |
| 2024Q4 | $0.46 | $0.63 | +37.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*